摘要
目的 分析贝伐珠单抗+奥沙利铂+卡培他滨联合用药方式对于直肠癌晚期患者的临床疗效。方法 选取2019年1月—2022年1月溧阳市人民医院收治的40例直肠癌晚期患者为研究对象,以随机数表法分为对照组和观察组,每组20例。对照组使用奥沙利铂+卡培他滨方案,观察组使用奥沙利铂+贝伐珠单抗+卡培他滨方案,对比两组患者的临床效果。结果 两组各项不良反应总发生率对比,差异无统计学意义(P>0.05)。观察组实际治疗有效率略高于对照组,但差异无统计学意义(P>0.05)。观察组患者的血清癌胚抗原水平为(10.81±1.04)ng/mL低于对照组的(14.96±3.85)ng/mL,差异有统计学意义(t=4.654,P<0.05)。观察组CD4^(+)、自然杀伤细胞及CD4^(+)/CD8+水平高于对照组,而CD8+低于对照组,差异有统计学意义(P<0.05)。结论 将卡培他滨片+奥沙利铂+贝伐珠单作为晚期直肠癌的治疗方案,效果显著。
Objective To analyze the clinical therapeutic efficacy of the combination of bevacizumab + oxaliplatin +capecitabine for patients with advanced rectal cancer.Methods 40 patients with advanced rectal cancer admitted to Liyang People's Hospital from January 2019 to January 2022 were selected as the study objects.They were randomly divided into a control group and an observation group by the method of chaotic number table,with 20 cases in each group.The control group centered on oxaliplatin + capecitabine treatment program,while the observation group intervened with the help of oxaliplatin + bevacizumab + capecitabine program,and the clinical effects of the two groups were compared.Results There was no statistically significant difference in the incidence of adverse reactions between the control group and the observation group(P>0.05).The actual treatment efficiency of the observation group was better than that of the control group,but the difference was not statistically significant(P>0.05).The carcinoembryonic antigen level of patients in the observation group was(10.81±1.04) ng/mL,which was lower than(14.96±3.85) ng/mL of the control group,and the difference was statistically significant(t=4.654,P<0.05).The levels of CD4~+,natural killing cells,and CD4~+/CD8~+ indexes in the observation group were higher than those in the control group,while CD8~+was lower than that in the control group,and the differences were statistically significant(P<0.05).Conclusion The application of capecitabine tablets + oxaliplatin + bevacizumab as an application program for the treatment of advanced rectal cancer is very effective.
作者
石贤清
SHI Xianqing(Department of Medical Oncology,Liyang People's Hospital,Changzhou,Jiangsu Province,213300 China)
出处
《中外医疗》
2023年第32期125-128,共4页
China & Foreign Medical Treatment
